Please login to the form below

Not currently logged in
Email:
Password:

MDR

This page shows the latest MDR news and features for those working in and with pharma, biotech and healthcare.

Pharma must do more on antibiotic resistance, Davos meeting hears

Pharma must do more on antibiotic resistance, Davos meeting hears

In particular, more needs to be done to bring forward new drugs for multidrug resistant (MDR) pathogens or ‘superbugs’ - there are currently 28 novel drugs for high-priority pathogens in phase

Latest news

  • Pfizer launches antibiotic resistance surveillance website Pfizer launches antibiotic resistance surveillance website

    Meanwhile, Pfizer’s new antibiotic for multidrug resistant (MDR) infections, Zavicefta, was launched in its first European markets earlier this year after the pharma firm paid its developer AstraZeneca $1.58bn

  • Pfizer launches new antibiotic Zavicefta in UK and Germany Pfizer launches new antibiotic Zavicefta in UK and Germany

    Pfizer launches new antibiotic Zavicefta in UK and Germany. Biopharmaceutical company Pfizer releases MDR antibiotic. ... Pfizer's new antibiotic for multidrug resistant (MDR) infections - Zavicefta - has been launched in the UK and Germany, its first EU

  • AZ slims down again with sale of antibiotics to Pfizer AZ slims down again with sale of antibiotics to Pfizer

    ATM-AVI is in trials for life-threatening Gram-negative bacterial infections caused by multi-drug resistant (MDR) strains, while CXL has activity against MDR Gram-positive and Gram-negative pathogens.

  • AZ gets EU green light for new antibiotic Zavicefta AZ gets EU green light for new antibiotic Zavicefta

    AstraZeneca's new antibiotic for multidrug resistant (MDR) infections - Zavicefta - has been approved for marketing in the EU. ... In 2014 Professor Sally Davies, the UK Chief Medical Officer, warned that countries are facing an 'apocalypse' if measures

  • Merck starts pivotal trials of new antibiotic combination Merck starts pivotal trials of new antibiotic combination

    Beta-lactamase inhibitor relebactam is a welcome addition to the late-stage antibiotics pipeline, which remains fairly sparse despite high levels of concern worldwide about multidrug resistant (MDR) infections. ... An independent UK review estimated in

More from news
Approximately 4 fully matching, plus 30 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics